In patients who switched from EU-ref-NTZ to biosim-NTZ at Week 24, treatment-related erythema and hypersensitivity reactions were reported at Day 169 (Week 24) in one patient who was ADA-negative at this time point, and was classified as persistently ADA-positive based on earlier timepoints (Supplementary Table S6). This evidence concerns the gene ADA and Erythema.